TG Therapeutics, Inc. , today announced that updated data for TG-1101 , the Company’s novel glycoengineered anti-CD20 monoclonal antibody, has been selected for presentation at the upcoming 69th American Academy of Neurology annual meeting, to be held April 22-28, 2017, in Boston, MA. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, stated, “We are very pleased to be able to present this early data from our Phase 2a study of TG-1101 in relapsing multiple sclerosis at the upcoming American Academy of Neurology annual meeting.